Company intelligence / Profile preview

MiCareo

Ownership: Private
Development stage: Commercial

Overview

MiCareo has developed and commercialized microfluidic-based platforms for isolating and analyzing rare cell populations from blood samples. Their systems are used for early cancer detection via circulating tumor cell analysis as well as immune monitoring in infectious disease contexts such as COVID-19 vaccination studies. The company’s technology enables high-purity live rare cell isolation with automated multiplexed fluorescence imaging for quantitative subtyping of individual cells[1][4].

Therapeutic areas: OncologyImmunology
Modalities: DeviceMicrofluidic technology (for rare cell isolation and analysis)AI-driven automation
Industry: Pathology

Partnerships

Collaborations with pharmaceutical companies for drug response monitoring and biomarker discovery are referenced but not named specifically[1]

Beyond the preview

Go deeper on MiCareo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MiCareo.

Explore the full profile